The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases
Background. Over the last 25 years, clinical practice guidelines have emerged as a means to standardize and improve care. As pharmaceutical innovations develop, guidelines are updated to incorporate new interventions. However, the extent to which pharmacotherapies are represented as treatment option...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | International Journal of Clinical Practice |
| Online Access: | http://dx.doi.org/10.1155/2024/5877687 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553063202684928 |
|---|---|
| author | Meaghan Roach Natalie Land Jennifer Hernandez Reina Rau Jacquelyn W. Chou Stacey S. Hickson Danielle F. Rollmann J. Ross Maclean |
| author_facet | Meaghan Roach Natalie Land Jennifer Hernandez Reina Rau Jacquelyn W. Chou Stacey S. Hickson Danielle F. Rollmann J. Ross Maclean |
| author_sort | Meaghan Roach |
| collection | DOAJ |
| description | Background. Over the last 25 years, clinical practice guidelines have emerged as a means to standardize and improve care. As pharmaceutical innovations develop, guidelines are updated to incorporate new interventions. However, the extent to which pharmacotherapies are represented as treatment options in guideline recommendations has not been well elucidated. This study aimed to quantify the role pharmacotherapy has played in clinical practice guidelines across a range of chronic diseases over the past 20 years. Methods. Clinical practice guidelines published from 2000 to 2021 were identified for five chronic diseases: ischemic heart disease (IHD), non-small cell lung cancer (NSCLC), chronic obstructive pulmonary disease (COPD), Alzheimer’s disease (AD), and type 2 diabetes (T2D). Guidelines were reviewed and data on treatment recommendations were collected, including the type of intervention, line of therapy, and, for pharmacotherapies, year of regulatory approval and year of inclusion in guidelines. Results. In total, 92 clinical practice guidelines were reviewed. Among the 184 discrete recommended interventions across the five disease areas, 146 (79.3%) were pharmacotherapies, 21 (11.4%) were behavioral modifications, 6 (3.3%) were surgical interventions, and 11 (6%) were other interventions. Across guidelines, when a line of therapy was specified, behavioral modifications and pharmacotherapies were most frequently recommended as first-line interventions, whereas surgical interventions were more often recommended for subsequent lines of treatment. The time from regulatory approval of novel pharmacotherapies to inclusion in guideline recommendations varied considerably by disease area and geography. Conclusions. Across the reviewed disease areas, behavioral interventions and pharmacotherapies are shown to be critical components of clinical practice. Over the last 20 years, novel pharmaceutical innovations have been incorporated into clinical practice guideline recommendations; however, with varying speeds of adoption. Given the increasing pace of pharmacologic innovation, timely updates of clinical practice guidelines are critical to evolving the standard of care and practicing evidence-based medicine. |
| format | Article |
| id | doaj-art-69cd0b85ade1499f83f8faee86ef3b13 |
| institution | Kabale University |
| issn | 1742-1241 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Clinical Practice |
| spelling | doaj-art-69cd0b85ade1499f83f8faee86ef3b132025-02-03T05:56:56ZengWileyInternational Journal of Clinical Practice1742-12412024-01-01202410.1155/2024/5877687The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic DiseasesMeaghan Roach0Natalie Land1Jennifer Hernandez2Reina Rau3Jacquelyn W. Chou4Stacey S. Hickson5Danielle F. Rollmann6J. Ross Maclean7PRECISIONheorPRECISIONheorPRECISIONheorPRECISIONheorPRECISIONheorJanssen Pharmaceuticals Inc.Janssen Pharmaceuticals Inc.PRECISIONheorBackground. Over the last 25 years, clinical practice guidelines have emerged as a means to standardize and improve care. As pharmaceutical innovations develop, guidelines are updated to incorporate new interventions. However, the extent to which pharmacotherapies are represented as treatment options in guideline recommendations has not been well elucidated. This study aimed to quantify the role pharmacotherapy has played in clinical practice guidelines across a range of chronic diseases over the past 20 years. Methods. Clinical practice guidelines published from 2000 to 2021 were identified for five chronic diseases: ischemic heart disease (IHD), non-small cell lung cancer (NSCLC), chronic obstructive pulmonary disease (COPD), Alzheimer’s disease (AD), and type 2 diabetes (T2D). Guidelines were reviewed and data on treatment recommendations were collected, including the type of intervention, line of therapy, and, for pharmacotherapies, year of regulatory approval and year of inclusion in guidelines. Results. In total, 92 clinical practice guidelines were reviewed. Among the 184 discrete recommended interventions across the five disease areas, 146 (79.3%) were pharmacotherapies, 21 (11.4%) were behavioral modifications, 6 (3.3%) were surgical interventions, and 11 (6%) were other interventions. Across guidelines, when a line of therapy was specified, behavioral modifications and pharmacotherapies were most frequently recommended as first-line interventions, whereas surgical interventions were more often recommended for subsequent lines of treatment. The time from regulatory approval of novel pharmacotherapies to inclusion in guideline recommendations varied considerably by disease area and geography. Conclusions. Across the reviewed disease areas, behavioral interventions and pharmacotherapies are shown to be critical components of clinical practice. Over the last 20 years, novel pharmaceutical innovations have been incorporated into clinical practice guideline recommendations; however, with varying speeds of adoption. Given the increasing pace of pharmacologic innovation, timely updates of clinical practice guidelines are critical to evolving the standard of care and practicing evidence-based medicine.http://dx.doi.org/10.1155/2024/5877687 |
| spellingShingle | Meaghan Roach Natalie Land Jennifer Hernandez Reina Rau Jacquelyn W. Chou Stacey S. Hickson Danielle F. Rollmann J. Ross Maclean The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases International Journal of Clinical Practice |
| title | The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases |
| title_full | The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases |
| title_fullStr | The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases |
| title_full_unstemmed | The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases |
| title_short | The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases |
| title_sort | role of pharmaceutical innovation in clinical practice guidelines for chronic diseases |
| url | http://dx.doi.org/10.1155/2024/5877687 |
| work_keys_str_mv | AT meaghanroach theroleofpharmaceuticalinnovationinclinicalpracticeguidelinesforchronicdiseases AT natalieland theroleofpharmaceuticalinnovationinclinicalpracticeguidelinesforchronicdiseases AT jenniferhernandez theroleofpharmaceuticalinnovationinclinicalpracticeguidelinesforchronicdiseases AT reinarau theroleofpharmaceuticalinnovationinclinicalpracticeguidelinesforchronicdiseases AT jacquelynwchou theroleofpharmaceuticalinnovationinclinicalpracticeguidelinesforchronicdiseases AT staceyshickson theroleofpharmaceuticalinnovationinclinicalpracticeguidelinesforchronicdiseases AT daniellefrollmann theroleofpharmaceuticalinnovationinclinicalpracticeguidelinesforchronicdiseases AT jrossmaclean theroleofpharmaceuticalinnovationinclinicalpracticeguidelinesforchronicdiseases AT meaghanroach roleofpharmaceuticalinnovationinclinicalpracticeguidelinesforchronicdiseases AT natalieland roleofpharmaceuticalinnovationinclinicalpracticeguidelinesforchronicdiseases AT jenniferhernandez roleofpharmaceuticalinnovationinclinicalpracticeguidelinesforchronicdiseases AT reinarau roleofpharmaceuticalinnovationinclinicalpracticeguidelinesforchronicdiseases AT jacquelynwchou roleofpharmaceuticalinnovationinclinicalpracticeguidelinesforchronicdiseases AT staceyshickson roleofpharmaceuticalinnovationinclinicalpracticeguidelinesforchronicdiseases AT daniellefrollmann roleofpharmaceuticalinnovationinclinicalpracticeguidelinesforchronicdiseases AT jrossmaclean roleofpharmaceuticalinnovationinclinicalpracticeguidelinesforchronicdiseases |